Acrivon Therapeutics Common Stock Filter Stocks by Fundamentals
ACRV Stock | 9.50 0.32 3.26% |
Acrivon Therapeutics Common fundamentals help investors to digest information that contributes to Acrivon Therapeutics' financial success or failures. It also enables traders to predict the movement of Acrivon Stock. The fundamental analysis module provides a way to measure Acrivon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acrivon Therapeutics stock.
Acrivon | Shares Owned by Insiders |
Acrivon Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Acrivon Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acrivon Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acrivon Therapeutics' value.Shares | State Street Corporation | 2023-12-31 | 133.3 K | Dafna Capital Management Llc | 2023-12-31 | 131.4 K | Ubs O'connor Llc | 2023-12-31 | 93.4 K | Northern Trust Corp | 2023-12-31 | 80.1 K | Charles Schwab Investment Management Inc | 2023-12-31 | 68.5 K | D. E. Shaw & Co Lp | 2023-09-30 | 46.8 K | Jpmorgan Chase & Co | 2023-12-31 | 33.3 K | Bridgeway Capital Management, Llc | 2023-12-31 | 32 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 25.6 K | Ra Capital Management, Llc | 2023-12-31 | 4.8 M | Perceptive Advisors Llc | 2023-12-31 | 3 M |
Acrivon Fundamentals
Return On Equity | -0.41 | ||||
Return On Asset | -0.26 | ||||
Current Valuation | 99.48 M | ||||
Shares Outstanding | 30.87 M | ||||
Shares Owned By Insiders | 17.56 % | ||||
Shares Owned By Institutions | 69.79 % | ||||
Number Of Shares Shorted | 532.96 K | ||||
Price To Book | 2.54 X | ||||
EBITDA | (66.7 M) | ||||
Net Income | (60.39 M) | ||||
Total Debt | 4.64 M | ||||
Book Value Per Share | 5.38 X | ||||
Cash Flow From Operations | (42.64 M) | ||||
Short Ratio | 6.03 X | ||||
Earnings Per Share | (2.74) X | ||||
Target Price | 19.44 | ||||
Number Of Employees | 58 | ||||
Market Capitalization | 303.16 M | ||||
Total Asset | 138.26 M | ||||
Retained Earnings | (116.42 M) | ||||
Working Capital | 116.39 M | ||||
Net Asset | 138.26 M |
About Acrivon Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acrivon Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acrivon Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acrivon Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Acrivon Stock
0.64 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
0.75 | ELYM | Eliem Therapeutics | PairCorr |
0.76 | ACB | Aurora Cannabis Trending | PairCorr |
Moving against Acrivon Stock
0.8 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
0.71 | GILD | Gilead Sciences Earnings Call Tomorrow | PairCorr |
0.63 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Acrivon Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acrivon Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acrivon Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acrivon Therapeutics Common to buy it.
The correlation of Acrivon Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acrivon Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acrivon Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acrivon Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Acrivon Therapeutics Piotroski F Score and Acrivon Therapeutics Altman Z Score analysis. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Acrivon Stock analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
CEOs Directory Screen CEOs from public companies around the world | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Commodity Directory Find actively traded commodities issued by global exchanges |
Is Acrivon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.26) | Return On Equity (0.41) |
The market value of Acrivon Therapeutics is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics' market value can be influenced by many factors that don't directly affect Acrivon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.